** Shares of telehealth firm Hims & Hers Health HIMS.N fall 7.3% to $53.78 premarket
** Late on Wednesday, health insurer Cigna CI.N said it will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans
** "The price point of $200/month is highly attractive compared to other price points in the market, including HIMS' compounded semaglutide at $399/month for 1-month subscription, Wegovy at $899/month for 1-month subscription"- brokerage Truist Securities
** Brokerage adds that HIMS has previously noted "it had very little interest in integrating insurance onto its platform", but, Cigna's weight losscoverage announcement "essentially challenges that argument"
** Brokerage estimates about $721 million of weight-loss drug-related revenues in 2025, which reflects weight-loss revenues and subscribers stepping down sequentially from Q1 to Q2
** Up to last close, stock more than doubled YTD
(Reporting by Sneha S K )
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.